close
  • Approved Use: Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.

You are now leaving aimovig.com

You are about to leave the aimovig.com website and enter a website operated by a third party. Amgen is not responsible for and does not endorse or control the content contained on this third-party website.

Continue

You are now leaving aimovig.com

You are about to leave the aimovig.com website and enter a website operated by a third party. Amgen & Novartis are not responsible for and do not endorse or control the content contained on this third-party website.

Continue
  1. Access to americanmigrainefoundation.org is not intended to provide medical advice or a referral to a particular physician;
  2. Patients should discuss with their physician their experience with the patient’s medical condition and should then determine if the physician is qualified to perform the procedure;
  3. Patients should discuss the risks and benefits of any procedure with their physician;
  4. americanmigrainefoundation.org is an independent entity, and not affiliated with, or an agent of, Amgen Inc.
  5. Amgen Inc. has not entered into any agreement with any doctor affiliated with americanmigrainefoundation.org to render any treatment or care to any patient, and has not evaluated the credentials, experience or expertise of any physician affiliated with, or referred through, americanmigrainefoundation.org.
  6. AMGEN INC. MAKES NO EXPRESS, IMPLIED OR STATUTORY WARRANTIES OR REPRESENTATIONS (INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE) AMERICANMIGRAINEFOUNDATION.ORG. TO THE MAXIMUM EXTENT PERMITTED BY LAW, AMGEN INC. AND ITS AFFILIATES ARE NOT RESPONSIBLE FOR AND EXPRESSLY DISCLAIM ALL LIABILITY, INCLUDING WITHOUT LIMITATION, FOR DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, AND SPECIAL OR OTHER DAMAGES ARISING FROM OR RELATED TO THE USE OF ANY SERVICES OFFERED BY AMERICANMIGRAINEFOUNDATION.ORG. BY ACCESSING AMERICANMIGRAINEFOUNDATION.ORG, YOU AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW THAT YOU WILL HOLD AMGEN INC. AND ITS AFFILIATES HARMLESS FROM ANY AND ALL CLAIMS ARISING FROM OR IN CONNECTION WITH ANY ACT OR OMISSION OF AMERICANMIGRAINEFOUNDATION.ORG.

You are now leaving aimovig.com

You are about to leave the aimovig.com website and enter a website operated by a third party. Amgen Inc. is not responsible for and does not endorse or control the content contained on this third-party website.

Click “OK” to proceed or “CANCEL” to return to aimovig.com

By clicking “OK” below, you acknowledge that you have read and reviewed the information contained within the Notice of Third-Party Site at the bottom of the page.

OK CANCEL

Paying for Aimovig

Learn more about the cost of Aimovig.

We have options that may help you.

The list price of Aimovig is $737.86 per month.* Most patients do not pay the list price. Your actual cost will vary. Talk to your insurance provider.

We have resources that can help. Eligible commercially insured patients pay as little as $5 per month† for Aimovig®.

†Eligibility criteria and program maximums apply. Terms and conditions apply.

*List price is also referred to as wholesale acquisition cost, or WAC. WAC is the price at which Amgen sells its products to wholesalers. Updated on Jan 04, 2023

Aimovig® Copay Card Terms and Conditions

SUMMARY OF TERMS AND CONDITIONS

    It is important that every patient read and understand the full Aimovig® (erenumab-aooe) Copay Card Terms and Conditions. The following summary is not a substitute for reviewing the Terms and Conditions in their entirety.

    As further described below, in general:

  • The Aimovig Copay Card is open to patients with commercial insurance, regardless of financial need. The program is not valid for patients whose Aimovig prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. It is not valid for cash-paying patients or where prohibited by law. (See ELIGIBILITY section in full Terms and conditions.)
  • With the Aimovig Copay Card, a commercially insured patient who meets eligibility criteria may pay as little as a $5 co-pay per month for their Aimovig monthly out-of-pocket costs. Monthly out-of-pocket costs include co-payment, co-insurance, and deductible out-of-pocket costs. Amgen will pay the remaining eligible out-of-pocket costs on behalf of the patient up to a Maximum Monthly Benefit, a Maximum Annual Program Benefit and/or the Patient Total Program Benefit. Patients are responsible for all amounts that exceed these limits. (See PROGRAM DETAILS section in full Terms and conditions.)
  • The program provides assistance up to a Maximum Monthly Benefit except that the Maximum Monthly Benefit will not apply to the first 2 uses of the Aimovig Copay Card for Aimovig in any given calendar year.
  • Offer is subject to change or discontinuation without notice.
  • The Aimovig Copay Card provides support up to the Maximum Monthly Benefit, the Maximum Annual Program Benefit and/or Patient Total Program Benefit. If a patient’s commercial insurance plan imposes different or additional requirements on patients who receive Aimovig Copay Card benefits, Amgen has the right to reduce or eliminate those benefits. Whether you are eligible to receive the Maximum Monthly Benefit, Maximum Program Benefit or Patient Total Program Benefit is determined by the type of plan coverage you have. Please ask your Aimovig All™ Support Team to help you understand eligibility for the Aimovig Copay Card, and whether your particular insurance coverage is likely to result in your reaching the Maximum Monthly Benefit, the Maximum Annual Program Benefit, or your Patient Total Program Benefit, by calling 1-833-AIMOVIG (1-833-246-6844). (See PROGRAM BENEFITS section in full Terms and conditions.)
Please see the full Terms and Conditions.

Select your insurance below:

  • I have private or commercial insurance

    75% of Aimovig prescriptions cost patients $5 or less per month.2,3 This number includes those where the Aimovig® Copay Card1 was used. The remaining 25% of Aimovig prescriptions cost patients an average of $82 per month.4,5

    • 1These data are based on the Aimovig® Copay Card paid claims data and paid claims data from national data providers for the period 4/1/2020 to 5/29/2020.
    • 2A one-month supply of Aimovig is typically administered as one injection once a month.
    • 3Eligibility criteria and limits apply. For more information about this program, see below.
    • 4These data are based on paid claims data from national data providers for the period 4/1/2020 to 5/29/2020.
    • 5Your actual cost may vary depending on your dose, insurance coverage, and eligibility for support programs. Talk to your insurance provider for specific information about your prescription coverage.
    Eligible commercially insured patients
    pay as little as
    $5 per month†
    for Aimovig®
    access card
    †Up to program maximums. Eligibility criteria and terms and conditions
    • †If approved by the patient’s health plan to take Aimovig® (erenumab-aooe), a patient pays as little as a $5 copay per month, up to an annual maximum benefit. This applies to patient out-of-pocket costs, including deductible, co-insurance, and copayments for Aimovig®. Patient is responsible for costs above the annual maximum. Terms and conditions apply.
    • ‡If the patient’s health plan does not cover Aimovig®, or requires a prior authorization, the patient can qualify for the Bridge to Commercial Coverage Offer and receive Aimovig® free for up to 3 doses, while pursuing approval from their health plan. No purchase necessary.Terms and conditions apply.

    Activate or get your card

    Have questions?

    Call our AimAlly™ Support Team at 833-AIMOVIG (833-246-6844), Monday–Friday, 8am–9pm et.

  • I have Medicare or Medicaid

    69% of Medicare Aimovig prescriptions cost patients $20 or less per month,1 and the remaining 31% of Medicare Aimovig prescriptions cost patients an average of $117 per month.2-5

    • 1A one-month supply of Aimovig is typically administered as one injection once a month.
    • 2These data are based on paid claims data from national data providers for the period 5/29/2019 to 5/29/2020.
    • 3Your out-of-pocket costs can vary throughout the year depending on which phase of the Part D benefit you are currently in. Medicare Part D drug coverage is divided into four phases, each with a different cost sharing amount. Those phases are 1) Deductible, 2) Initial coverage, 3) Coverage gap, 4) Catastrophic.
    • 4These amounts may vary if you are eligible for the Extra Help program. For more information, please visit Extra Help with Medicare Prescription Drug Plan Costs from the Social Security Administration (SSA) at https://www.ssa.gov/benefits/medicare/prescriptionhelp. Accessed on July 18, 2019.
    • 5Your actual cost may vary depending on your dose and insurance coverage. Talk to your insurance provider for specific information about your prescription coverage.

    99% of Medicaid Aimovig prescriptions cost patients $10 or less per month,1 and the remaining 1% of Medicaid Aimovig prescriptions cost patients an average of $128 per month.2-4

    • 1A one-month supply of Aimovig is typically administered as one injection once a month.
    • 2These data are based on paid claims data from national data providers for the period 4/1/2020 to 5/29/2020.
    • 3Find out more about Medicaid benefits in your state, including whether you may be eligible for Medicaid at https://www.healthcare.gov/medicaid-chip/.
    • 4Your actual cost may vary depending on your dose and insurance coverage. Talk to your insurance provider for specific information about your prescription coverage.

    Patients with Medicare or Medicaid may be eligible for Aimovig coverage under their health insurance plan. To find out if you’re covered, call your insurance provider today.

  • I do not have insurance

    amgen-safety-net-foundation

    The Amgen Safety Net Foundation is an independent, nonprofit patient assistance program that provides Aimovig at no cost to qualifying patients who have a financial need and are uninsured or have insurance that excludes Aimovig.

    Take me to the Amgen
    Safety Net Foundation

Frequently asked questions

  • Where can I get Aimovig?
    You can go to most any pharmacy to fill your Aimovig prescription.
  • Does Amgen offer a program to help lower the cost of my treatment?
    If you have commercial insurance that covers Aimovig, you may pay as little as a $5 per month, up to program maximums with the Aimovig® Copay Card. Eligibility criteria and terms and conditions apply.
  • How can I sign up for the
    Aimovig® Copay Card?
    Learn more about the Aimovig® Copay Card at www.aimovigcopaycard.com
  • Is Aimovig covered by commercial insurance?

    Everyone’s coverage is different. The best way to know if you plan covers Aimovig is to call your insurance provider or call AimAlly™ at 1-833-AIMOVIG (1-833-246-6844), 8 AM-9 PM ET, Mon-Fri, and we can discuss your individual options.

  • Is Aimovig covered by federal insurance programs (Medicaid, Medicare, and Tricare?)
    Every federally insured patient’s coverage is different. The best way to know your individual options is by calling your insurance provider or our support team. Please know we are committed to identifying access to financial resources to help make Aimovig accessible to as many prescribed patients as possible. For more information, call AimAlly™ at 1-833-AIMOVIG (1-833-246-6844), 8AM-9PM ET, Mon-Fri.
  • Who can I talk to if I have questions about insurance?
    Call AimAlly™ at 1-833-AIMOVIG (1-833-246-6844), 8AM-9PM ET, Mon-Fri.

Contact us here

1-833-AIMOVIG (1-833-246-6844)

8AM–9PM ET, Mon–Fri

+ +

Important Safety Information

Who should not use Aimovig®?
Do not use Aimovig if you are allergic to erenumab-aooe or any ingredients in

Who should not use Aimovig? Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®. Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you are allergic to rubber or latex, pregnant or plan to become pregnant, breastfeeding or plan to breastfeed.

 
–

Important Safety Information

Who should not use Aimovig®? Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®. Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you are allergic to rubber or latex, pregnant or plan to become pregnant, breastfeeding or plan to breastfeed. Tell your HCP about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements. What are possible side effects of Aimovig®? Aimovig® may cause serious side effects, including:
  • Allergic reactions. Allergic reactions, including rash or swelling can happen after receiving Aimovig®. This can happen within hours to days after using Aimovig®. Call your HCP or get emergency medical help right away if you have any of the following symptoms of an allergic reaction: swelling of the face, mouth, tongue or throat, or trouble breathing.
  • Constipation with serious complications. Severe constipation can happen after receiving Aimovig®. In some cases people have been hospitalized or needed surgery. Contact your HCP if you have severe constipation.
  • High blood pressure. High blood pressure or worsening of high blood pressure can happen after receiving Aimovig®. Contact your healthcare provider if you have an increase in blood pressure.
The most common side effects of Aimovig® are pain, redness, or swelling at the injection site and constipation. These are not all of the possible side effects of Aimovig®. Call your HCP for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Click here for the full Prescribing Information and Patient Product Information.

Approved Use

Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.
References: 1. Parsabiv® (etelcalcetide) prescribing information, Amgen. 2. Data on file, Amgen; [Summary of Clinical Efficacy; 2015]. 3. Alexander ST, et al. Mol Pharmacol. 2015;88:853-865. 4. Data on file, Amgen; [Report R20130052, 2014]. 5. Chen P, et al. CPT Pharmacometrics Syst Pharmacol. 2016;5:484-494. 6. Sensipar® (cinacalcet) prescribing information, Amgen. 7. Ma JN, et al. J Pharmacol Exp Ther. 2011;337:275-284.